Xiaoyun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoyun Zhang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Li
Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Tian-Fu Wen
West China Hospital of Sichuan University
2 shared publications - Tianfu Wen
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Wei Peng
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Changli Lu
Department of Pathology,West China Hospital,Sichuan University,Chengdu,China
1 shared publication- Chuan Li
West China Hospital of Sichuan University
1 shared publication
Latest Publications
- Open Access
- 13 October 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (23) , 8421-8431
Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus‐related hepatocellular carcinoma after surgical resection: A multicenter study
Background Antiviral therapy should reduce the recurrence of hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) after surgical resection. However, there is little research on whether various antiviral drugs have different prognostic effects in patients with HBV-related HCC after curative liver resection. The present study compared the effects of nucleotide analog (NtA) and nucleoside analog (NsA) antiviral therapies after surgical resection on the prognosis of HBV-related HCC. Methods A total of 1303 patients with HBV-related HCC who received curative hepatectomy at five institutes between April 2014 and April 2019 were retrospectively enrolled and analyzed. Propensity matching analysis was used to compare the outcomes of HCC patients given NsA versus NtA therapy. Subgroup analysis of patients treated with entecavir (ETV) and tenofovir disoproxil fumarate (TDF) was also performed. Results Among 1303 patients, 759 (58.2%) patients developed recurrence, and 460 (35.3%) patients died. Multivariable analyses revealed that NtA therapy significantly decreased the risk of HCC recurrence (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.51–0.80; p < 0.001) and HCC-related death (HR, 0.52; 95% CI, 0.36–0.76; p = 0.001) compared to that with NsA therapy. Subgroup analysis showed that TDF treatment was associated with significantly lower rates of HCC recurrence (HR, 0.64; 95% CI, 0.49–0.83; p = 0.001) and death (HR, 0.32; 95% CI, 0.20–0.50; p < 0.001) than ETV treatment. Conclusions Nucleotide analog treatment, but not NsA treatment, significantly reduced the risk of HCC recurrence in patients with HBV-related HCC and improved overall survival after curative hepatic resection.
- 13 October 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (23) , 8421-8431
Open AccessComparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus‐related hepatocellular carcinoma after surgical resection: A multicenter study
Background Antiviral therapy should reduce the recurrence of hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) after surgical resection. However, there is little research on whether various antiviral drugs have different prognostic effects in patients with HBV-related HCC after curative liver resection. The present study compared the effects of nucleotide analog (NtA) and nucleoside analog (NsA) antiviral therapies after surgical resection on the prognosis of HBV-related HCC. Methods A total of 1303 patients with HBV-related HCC who received curative hepatectomy at five institutes between April 2014 and April 2019 were retrospectively enrolled and analyzed. Propensity matching analysis was used to compare the outcomes of HCC patients given NsA versus NtA therapy. Subgroup analysis of patients treated with entecavir (ETV) and tenofovir disoproxil fumarate (TDF) was also performed. Results Among 1303 patients, 759 (58.2%) patients developed recurrence, and 460 (35.3%) patients died. Multivariable analyses revealed that NtA therapy significantly decreased the risk of HCC recurrence (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.51–0.80; p < 0.001) and HCC-related death (HR, 0.52; 95% CI, 0.36–0.76; p = 0.001) compared to that with NsA therapy. Subgroup analysis showed that TDF treatment was associated with significantly lower rates of HCC recurrence (HR, 0.64; 95% CI, 0.49–0.83; p = 0.001) and death (HR, 0.32; 95% CI, 0.20–0.50; p < 0.001) than ETV treatment. Conclusions Nucleotide analog treatment, but not NsA treatment, significantly reduced the risk of HCC recurrence in patients with HBV-related HCC and improved overall survival after curative hepatic resection.
- Open Access
- 2 March 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (2) , 797-815
Brahma‐Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion
Intrahepatic cholangiocarcinoma (iCCA) is closely correlated with hepatic progenitor cell (HPC) expansion and liver fibrosis. Brahma‐related gene 1 (Brg1), an enzymatic subunit of the SWltch/Sucrose Non‐Fermentable (SWI/SNF) complex that is critical in stem cell maintenance and tumor promotion, is prominently up‐regulated in both HPCs and iCCA; however, its role in this correlation remains undefined. A retrospective cohort study indicated that high Brg1 expression suggests poor prognosis in iCCA patients. In chronically injured livers induced by a 0.1% 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) diet or bile duct ligation (BDL) surgery, HPCs were dramatically activated, as indicated by their enhanced expression of Brg1 and a subset of stem cell markers; however, Brg1 ablation in HPCs strongly suppressed HPC expansion and liver fibrosis. Furthermore, in a chemically induced iCCA model, inhibition of Brg1 by a specific inhibitor or inducible gene ablation markedly improved histology and suppressed iCCA growth. Mechanistically, in addition to transcriptionally promoting both Wnt receptor genes and target genes, Brg1 was found to bind to the β‐catenin/transcription factor 4 (TCF4) transcription complex, suggesting a possible novel approach for regulation of Wnt/β‐catenin signaling. Conclusion: We have demonstrated the function of Brg1 in promoting HPC expansion, liver cirrhosis, and ultimately iCCA development in chronically injured livers, which is largely dependent on Wnt/β‐catenin signaling. Our data suggest that therapies targeting Brg1‐expressing HPCs are promising for the treatment of liver cirrhosis and iCCA.
- 2 March 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (2) , 797-815
Open AccessBrahma‐Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion
Intrahepatic cholangiocarcinoma (iCCA) is closely correlated with hepatic progenitor cell (HPC) expansion and liver fibrosis. Brahma‐related gene 1 (Brg1), an enzymatic subunit of the SWltch/Sucrose Non‐Fermentable (SWI/SNF) complex that is critical in stem cell maintenance and tumor promotion, is prominently up‐regulated in both HPCs and iCCA; however, its role in this correlation remains undefined. A retrospective cohort study indicated that high Brg1 expression suggests poor prognosis in iCCA patients. In chronically injured livers induced by a 0.1% 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) diet or bile duct ligation (BDL) surgery, HPCs were dramatically activated, as indicated by their enhanced expression of Brg1 and a subset of stem cell markers; however, Brg1 ablation in HPCs strongly suppressed HPC expansion and liver fibrosis. Furthermore, in a chemically induced iCCA model, inhibition of Brg1 by a specific inhibitor or inducible gene ablation markedly improved histology and suppressed iCCA growth. Mechanistically, in addition to transcriptionally promoting both Wnt receptor genes and target genes, Brg1 was found to bind to the β‐catenin/transcription factor 4 (TCF4) transcription complex, suggesting a possible novel approach for regulation of Wnt/β‐catenin signaling. Conclusion: We have demonstrated the function of Brg1 in promoting HPC expansion, liver cirrhosis, and ultimately iCCA development in chronically injured livers, which is largely dependent on Wnt/β‐catenin signaling. Our data suggest that therapies targeting Brg1‐expressing HPCs are promising for the treatment of liver cirrhosis and iCCA.
- 14 December 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 63 (2) , 502-514
Outcomes of Salvage Liver Transplantation and Re-resection/Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: A New Surgical Strategy Based on Recurrence Pattern
The treatment of intrahepatic recurrent hepatocellular carcinoma (HCC) has been poorly investigated, and the optimal treatment strategy remains unclear.
- 14 December 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 63 (2) , 502-514
Outcomes of Salvage Liver Transplantation and Re-resection/Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: A New Surgical Strategy Based on Recurrence Pattern
The treatment of intrahepatic recurrent hepatocellular carcinoma (HCC) has been poorly investigated, and the optimal treatment strategy remains unclear.